“For me, the biggest payoff in cancer research would be the discovery of biomarkers that can be measured in the blood that reflect the presence of early stage cancer. For nearly all cancers, early detection means cure by standard treatments of surgery and radiation”
Dr. Leland H. Hartwell
Nobel Laureate, President, Fred Hutchinson Cancer Research Center
At Paradise Genomics, we have cracked the code for RNA based biomarkers and have uncovered the secrets behind the dynamic nature of diseases.
The NIH defines biomarkers as biological molecules found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. In the world of disease research, biomarkers can be both DNA and dynamic RNA biomarkers. At Paradise Genomics, we believe in the power of RNA based biomarkers in truly revealing the secrets behind the dynamic nature of diseases. While other biomarkers like proteins can be limited by technology, RNA gives an overview of every gene expressed in the body.
Through 30 years of experience in genomic analysis, we’ve developed and refined a novel and proprietary process that uncovers more biomarkers than conventional techniques. These dynamic biomarkers give leading medical device, pharmaceutical and biotechnology companies the actionable genomic data they need for product innovation in clinical diagnostics, prognostics, therapeutic monitoring and drug discovery.